磷脂酰肌醇蛋白聚糖-3和甲胎蛋白联合检测对原发性肝癌的诊断价值

宋孟锜; 杨永飞; 王冬冬; 由法平; 陈立波

磷脂酰肌醇蛋白聚糖-3和甲胎蛋白联合检测对原发性肝癌的诊断价值

华中科技大学同济医学院附属协和医院肝胆外科

基金项目:

国家自然科学基金资助项目(30672067,30700190)；教育部新世纪优秀人才支持计划基金资助项目(NCET-07-318)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 4239
- HTML全文浏览量: 13
- PDF下载量: 1093
- 被引次数: 0
出版历程
- 收稿日期: 2010-10-25
- 出版日期: 2011-04-20

The diagnostic role of combination of glypican-3 and AFP in primary hepatic carcinoma

Research funding:

摘要

摘要: 目的通过联合检测磷脂酰肌醇蛋白聚糖-3（GPC3）、甲胎蛋白（AFP）在原发性肝癌患者血清及组织中的表达情况,探讨对原发性肝癌的诊断价值。方法分别采用ELISA和免疫组织化学法检测57例肝癌、74例肝炎后肝硬化患者和47例正常血清和肝组织GPC3、AFP表达水平,根据不同临床病理指标进行分组比较。结果（1）肝癌患者、肝炎后肝硬化及正常对照者血清中GPC3水平分别为（212.6±137.5）、（60.9±27.8）、（39.5±18.7）ng/ml;肝癌患者血清GPC3浓度显著高于正常及肝炎后肝硬化患者（t=4.503,P<0.05;t=6.045,P<0.05）;血清GPC3、AFP联合检测原发性肝癌的敏感性和特异性为84.2%和95.7%,均显著高于任一单项检测（t=4.132,P<0.05;t=6.514,P<0.05）;（2）GPC3在肝癌组织表达高于癌旁和正常肝组织（t=3.724,P<0.05;t=15.799,P<0.05）;GPC3与肿瘤大小、肿瘤数目、HBsAg及AFP水平无明显相关,而与病理分级和临床分期有关;（3）AFP阳性肝癌...
- 肝肿瘤 /
- 磷脂酰肌醇蛋白聚糖类 /
- 甲胎蛋白类
Abstract: Objective To detect the expression of Glypican-3 (GPC3) and α-fetoprotein (AFP) in serum and tissues of hepatic carcinoma patients.Methods ELISA and immunohistochemical staining were applied to detect GPC3 and AFP expressing level in the serum and tissues in 57 cases with primary hepatic carcinoma (PHC) and tumor-adjacent specimens were also detected, 74 cases with post-hepatitis cirrhosis and 47 normal liver specimens.Correlation of combined expression of GPC3 and AFP and clinical pathology parameters was analyzed.Results The expression level of GPC3 in the serum of PHC and post-hepatitis cirrhosis patients and healthy people is (212.6±137.5) ng/ml, (60.9±27.8) ng/ml and (39.5±18.7) ng/ml respectively.GPC3 level in the serum of PHC was significantly higher than that of post-hepatitis cirrhosis and healthy people (t=4.503, P<0.05;t=6.045, P<0.05) .Sensitivity and specificity of combined detection of GPC3 and AFP was 84.2% and 95.7% respectively in PHC, which was significantly higher than that of any individual detection (t=4.132, P<0.05;t=6.514, P<0.05) .The expression level of GPC3 was significantly higher in PHC than tumor-adjacent tissue and normal liver tissue (t=3.724, P<0.05;t=15.799, P<0.05) .The expression of GPC3 was positively correlated with pathological grade and clinical stage, but not with tumor size, tumor number and the level of HBsAg or AFP in serum.The positive rate of GPC3 in serum of AFP-negative PHC was 59.1% while 91.4% in the AFP-positive PHC.Conclusion Detection Combined with GPC3 and AFP can improve the sensitivity and specificity of PHC, and detecting GPC3 may improve the diagnostic rate of AFP-negative PHC.
- liver neoplasms /
- glypicans /
- alpha-Fetoproteins

HTML全文

参考文献(17)

[1]Poon D, Anderson BO, Chen LT, et al.Management ofhepatocellular carcinoma in Asia:consensus statement fromthe Asian Oncology Summit 2009[J].Lancet Oncol, 2009, 10 (11) :1111-1118.

[2]Marrero JA, Feng Z, Wang Y, et al.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-boundalpha-fetoprotein in early hepatocellular carcinoma[J].Gastroenterology, 2009, 137 (1) :110-118.

[3]Capurro M, Filmus J.Glypican-3 as a serum marker forhepatocellular carcinoma[J].Cancer Res, 2005, 65 (1) :372-373.

[4]毛伟征, 苏东明, 李雪萍, 等.AJCC癌症分期手册[M].沈阳:辽宁科学技术出版社, 2005:133.

[5]申洪.免疫组织化学染色定量方法研究 (III) [J].中国组织化学与细胞化学杂志, 1995, 4 (1) :89-91.

[6]De Cat B, David G.Developmental roles of the glypicans[J].Seminars in Cell&Developmental Biology, 2001, 12 (2) :117-125.

[7]Llovet JM, Chen Y, Friedman SL, et al.A molecular signatureto discriminate dysplastic nodules from early hepatocellularcarcinoma in HCV cirrhosis[J].Gastroenterology, 2006, 131 (6) :1758-1767.

[8]Nakatsura T, Yoshitake Y, Senju S, et al.Glypican-3, overexpressed specifically in human hepatocellularcarcinoma, is a novel tumor marker[J].Biochem BiophysRes Commun, 2003, 306 (1) :16-25.

[9]Capurro M, Wanless IR, Sherman M, et al.Glypican-3:Anovel serum and histochemical marker for hepatocellularcarcinoma[J].Gastroenterology, 2003, 125 (1) :89-97.

[10]Hippo Y, Watanabe K, Wantanbe A, et al.Identificationof soluble NH2-terminal fragment of glypican-3 asa serological marker for early-stage hepatocellularcarcinoma[J].Cancer Res, 2004, 64 (7) :2418-2423.

[11]Zhu ZW, Friess H, Wang L, et al.Enhanced glypican-3 expressiondifferentiates the majority of hepatocellular carcinomas frombenign hepatic disorders[J].Gut, 2001, 48 (4) :558-564.

[12]Zhou XP, Wang HY, Yang GS, et al.Cloning and expressionof MXR7 gene in human HCC tissue[J].World JGastroenterol, 2000, 6 (1) :57-60.

[13]Libbrecht L, Severi T, Cassiman D, et al.Glypican-3 expression distinguishes small hepatocellular carcinomas fromcirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules[J].Am J Surg Pathol, 2006, 30 (11) :1405-1411.

[14]Shafizadeh N, Ferrell LD, Kakar S.Utility and limitations ofglypican-3 expression for the diagnosis of hepatocellularcarcinoma at both ends of the differentiation spectrum[J].Mod Pathol, 2008, 21 (8) :1011-1018.

[15]Wang DS, Ding HG, Li Z, et al.The diagnostic value of combination with GPC3 and AFP in hepatocellular carcinomas[J].Zhonghua Jianyan Yixue Zazhi, 2007, 30 (10) :1169-1171.

[16]Jia HL, Ye QH, Qin LX, et al.Gene expression profilingrev-eals potential biomarkers of human hepatocellularcarcinoma[J].Clin Cancer Res, 2007, 13 (4) :1133-1139.

[17]王钰.原发性肝癌血清肿瘤标记物检测研究进展[J].吉林医学, 2010, 31 (7) :988-989.

施引文献

资源附件(0)

访问统计